Protocol Ledger

NCT04281485 · Phase III · ACTIVE NOT RECRUITING

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Interventional Phase III clinical trial protocol NCT04281485 sponsored by Pfizer in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-05 Enrollment: 114 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04281485
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)114 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04281485
Protocol FieldVerified Registry Value
NCT IdentifierNCT04281485
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment114 participants (ACTUAL)
Registered Start Date2020-11-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI